Build status - In Progress

A Phase 1 Study of the Highly-selective RET

A Phase 1 Study of the Highly-selective RET
Recruiting
99 years or below
All
Phase 1
5 participants needed
1 Location

Brief description of study

This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated dose(MTD) of Blu-667 and recommend a dosage for Phase 2 portion of the trial

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ['RET-altered Non Small Cell Lung Cancer', 'Medullary Thyroid Cancer', 'RET-altered Papillary Thyroid Cancer', 'RET-altered Colon Cancer', 'RET-altered Solid Tumors']
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 826593

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center